Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
Abstract Introduction Preventive therapy is essential for reducing tuberculosis (TB) burden among people living with HIV (PLWH) in high‐burden settings. Short‐course preventive therapy regimens, such as three‐month weekly rifapentine and isoniazid (3HP) and one‐month daily rifapentine and isoniazid (1HP), may help facilitate uptake of preventive therapy for latently infected patients, but the comparative cost‐effectiveness of these regimens under different conditions is uncertain. Methods We used a Markov state‐transition model to estimate the incremental costs and effectiveness of 1HP versus 3HP in a simulated cohort of patients attending an HIV clinic in Uganda, as an example of a low‐income, high‐burden setting in which TB preventive therapy might be prescribed to PLWH. Our primary outcome was the incremental cost‐effectiveness ratio, expressed as 2019 US dollars per disability‐adjusted life year (DALY) averted. We estimated cost‐effectiveness under different conditions of treatment completion and efficacy of 1HP versus 3HP, latent TB prevalence and rifapentine price. Results Assuming equivalent clinical outcomes using 1HP and 3HP and a rifapentine price of $0.21 per 150 mg, 1HP would cost an additional $4.66 per patient treated. Assuming equivalent efficacy but 20% higher completion with 1HP versus 3HP, 1HP would cost $1,221 per DALY averted relative to 3HP. This could be reduced to $18 per DALY averted if 1HP had 5% greater efficacy than 3HP and the price of rifapentine were 50% lower. At a rifapentine price of $0.06 per 150 mg, 1HP would become cost‐neutral relative to 3HP. Conclusions1HP has the potential to be cost‐effective under many realistic circumstances. Cost‐effectiveness depends on rifapentine price, relative completion and efficacy, prevalence of latent TB and local willingness‐to‐pay..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of the International AIDS Society - 23(2020), 10 |
| Beteiligte Personen: |
Ferguson, Olivia [VerfasserIn] |
|---|
| Anmerkungen: |
© 2020 International AIDS Society |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/jia2.25623 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY008857571 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY008857571 | ||
| 003 | DE-627 | ||
| 005 | 20230307182205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/jia2.25623 |2 doi | |
| 028 | 5 | 2 | |a JIA2_JIA225623.xml |
| 035 | |a (DE-627)WLY008857571 | ||
| 035 | |a (WILEY)JIA225623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |a 300 |q ASE |
| 100 | 1 | |a Ferguson, Olivia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda |
| 264 | 1 | |c 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 International AIDS Society | ||
| 520 | |a Abstract Introduction Preventive therapy is essential for reducing tuberculosis (TB) burden among people living with HIV (PLWH) in high‐burden settings. Short‐course preventive therapy regimens, such as three‐month weekly rifapentine and isoniazid (3HP) and one‐month daily rifapentine and isoniazid (1HP), may help facilitate uptake of preventive therapy for latently infected patients, but the comparative cost‐effectiveness of these regimens under different conditions is uncertain. Methods We used a Markov state‐transition model to estimate the incremental costs and effectiveness of 1HP versus 3HP in a simulated cohort of patients attending an HIV clinic in Uganda, as an example of a low‐income, high‐burden setting in which TB preventive therapy might be prescribed to PLWH. Our primary outcome was the incremental cost‐effectiveness ratio, expressed as 2019 US dollars per disability‐adjusted life year (DALY) averted. We estimated cost‐effectiveness under different conditions of treatment completion and efficacy of 1HP versus 3HP, latent TB prevalence and rifapentine price. Results Assuming equivalent clinical outcomes using 1HP and 3HP and a rifapentine price of $0.21 per 150 mg, 1HP would cost an additional $4.66 per patient treated. Assuming equivalent efficacy but 20% higher completion with 1HP versus 3HP, 1HP would cost $1,221 per DALY averted relative to 3HP. This could be reduced to $18 per DALY averted if 1HP had 5% greater efficacy than 3HP and the price of rifapentine were 50% lower. At a rifapentine price of $0.06 per 150 mg, 1HP would become cost‐neutral relative to 3HP. Conclusions1HP has the potential to be cost‐effective under many realistic circumstances. Cost‐effectiveness depends on rifapentine price, relative completion and efficacy, prevalence of latent TB and local willingness‐to‐pay. | ||
| 700 | 1 | |a Jo, Youngji |4 aut | |
| 700 | 1 | |a Pennington, Jeff |4 aut | |
| 700 | 1 | |a Johnson, Karl |4 aut | |
| 700 | 1 | |a Chaisson, Richard E |4 aut | |
| 700 | 1 | |a Churchyard, Gavin |4 aut | |
| 700 | 1 | |a Dowdy, David |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the International AIDS Society |g 23(2020), 10 |w (DE-627)WLY008856117 |x 17582652 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2020 |g number:10 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2020 |e 10 |g 8 | ||